These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2653325)

  • 1. Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes.
    Riccardi G; Genovese S; Saldalamacchia G; Patti L; Marotta G; Postiglione A; Rivellese A; Capaldo B; Mancini M
    Atherosclerosis; 1989 Feb; 75(2-3):175-81. PubMed ID: 2653325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
    Taniguchi A; Fukushima M; Sakai M; Tokuyama K; Nagata I; Fukunaga A; Kishimoto H; Doi K; Yamashita Y; Matsuura T; Kitatani N; Okumura T; Nagasaka S; Nakaishi S; Nakai Y
    Metabolism; 2001 Apr; 50(4):477-80. PubMed ID: 11288046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus.
    Alberti KG; Jones IR; Laker MF; Swai AB; Taylor R
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S21-4; discussion S24-5. PubMed ID: 1710741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis.
    Mikhailidis DP; Mathur S; Barradas MA; Dandona P
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():platelet inhib/pd/ad/ae. PubMed ID: 1710742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bezafibrate affects lipid, lipo- and apolipoprotein pattern in non-insulin-dependent diabetic patients.
    Niort G; Gambino R; Cassader M; Pagano G
    Horm Metab Res; 1993 Jul; 25(7):372-4. PubMed ID: 8406323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia.
    Rovellini A; Sommariva D; Branchi A; Maraffi F; Montalto C; Gandini R; Fasoli A
    Pharmacol Res; 1992 Apr; 25(3):237-45. PubMed ID: 1518767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
    Smud R; Sermukslis B
    Curr Med Res Opin; 1987; 10(9):612-24. PubMed ID: 3436157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bezafibrate retard in patients with insulin-dependent diabetes: effect on serum lipoproteins, fibrinogen, and glycemic control.
    Durrington PN; Winocour PH; Bhatnagar D
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S30-4. PubMed ID: 1710743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM.
    Jones IR; Swai A; Taylor R; Miller M; Laker MF; Alberti KG
    Diabetes Care; 1990 Aug; 13(8):855-63. PubMed ID: 2209320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bezafibrate on hypercoagulability assessed by fluorogenic prothrombin time in hyperlipidemic patients with non-insulin-dependent diabetes mellitus.
    Yoshinari M; Yamamoto M; Waklsaka M; Iwase M; Takano K; Fujishlma M
    Thromb Res; 1997 Jun; 86(6):443-51. PubMed ID: 9219324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of bezafibrate on in vivo VLDL-triglyceride production in the rat.
    Kazumi T; Yoshino G; Iwai M; Matsuba K; Matsushita M; Iwatani I; Kasama T; Yoshida M; Baba S
    Diabetes Res Clin Pract; 1990; 9(2):163-8. PubMed ID: 2198155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia.
    Bradford RH; Goldberg AC; Schonfeld G; Knopp RH
    Atherosclerosis; 1992 Jan; 92(1):31-40. PubMed ID: 1575820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bezafibrate reduces blood glucose in type 2 diabetes mellitus.
    Ogawa S; Takeuchi K; Sugimura K; Fukuda M; Lee R; Ito S; Sato T
    Metabolism; 2000 Mar; 49(3):331-4. PubMed ID: 10726910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
    Prager R; Schernthaner G; Kostner GM; Mühlhauser I; Zechner R; Dorda W
    Atherosclerosis; 1982 Jun; 43(2-3):321-7. PubMed ID: 6810904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus.
    Winocour PH; Durrington PN; Bhatnagar D; Ishola M; Arrol S; Lalor BC; Anderson DC
    Diabet Med; 1990; 7(8):736-43. PubMed ID: 2147637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients.
    Niort G; Cassader M; Gambino R; Pagano G
    Diabete Metab; 1992; 18(3):221-8. PubMed ID: 1397477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
    Franko A; Neschen S; Rozman J; Rathkolb B; Aichler M; Feuchtinger A; Brachthäuser L; Neff F; Kovarova M; Wolf E; Fuchs H; Häring HU; Peter A; Hrabě de Angelis M
    Mol Metab; 2017 Mar; 6(3):256-266. PubMed ID: 28271032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
    Winocour PH; Durrington PN; Bhatagnar D; Ishola M; Mackness M; Arrol S; Anderson DC
    Atherosclerosis; 1992 Mar; 93(1-2):83-94. PubMed ID: 1596307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance.
    Inoue I; Takahashi K; Katayama S; Akabane S; Negishi K; Suzuki M; Ishii J; Kawazu S
    Diabetes Res Clin Pract; 1994 Oct; 25(3):199-205. PubMed ID: 7851275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A therapeutic trial of bezafibrate on patients with hyperlipidemia with or without diabetes mellitus.
    Ho LT; Chiang HL; Tsai H; Chou TY; Kwok CF
    Proc Natl Sci Counc Repub China B; 1984 Jul; 8(3):240-5. PubMed ID: 6571590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.